Introduction
Staphylococcus aureus harbors several virulence factors that increase its ability to adhere, colonize and invade tissues and sequentially increase the pathogenicity. 1, 2 Liver transplant recipients have a greater propensity to S. aureus colonization/infections than other solid organ transplant patients because of the complexity of the surgical procedure and the frequent use of intravascular catheters. 3 S. aureus bacteremias represented 23.5% of all S. aureus infections and complicated the clinical course of liver transplantation (LT). 4, 5 Methicillin-resistant S. aureus (MRSA) bacteremias represented 42%-69% of all MRSA infections after LT and increased duration of hospitalization, costs, morbidity and mortality.
Relevant morbidity and mortality rates of S. aureus/MRSA bacteremia S. aureus bacteremia has been reported to have an incidence range of 1%-23.5% and has been responsible for 24% of all bacteremias in patients with liver cirrhosis. [9] [10] [11] [12] [13] The incidence of S. aureus bacteremia increased from 1.2% before LT to 9.6% after LT, which means S. aureus bacteremia is easier to occur in liver recipients than in liver cirrhotic patients. 9 The morbidity of S. aureus bacteremia varied from 0.6% to 29% among liver recipients, 5, 9, and for MRSA bacteremia, it was 0.4%-27.4%. 5, 6, 9, 14, 15, 17, 19, 22, 23, 26, 35, [37] [38] [39] [40] According to a study conducted at the Pittsburgh VA Medical Center, of 233 consecutive liver recipients, 3.8% underwent MRSA bacteremia during [1989] [1990] [1991] [1992] [1993] 24 .5% during 1993-1995, 30% during 1996-1998 and 11.3% during 1998-2003. 37 The mortality rate in liver recipients with S. aureus bacteremia and MRSA bacteremia has been identified to be 20%-46% 34, 39, 41 and 15%-60%, 4, 27, 37, 38 respectively. For those patients with MRSA bacteremia accompanied by pneumonia and abdominal infections, death rate was up to 86%. 4 The mortality rates of S. aureus/MRSA bacteremia among liver recipients are illustrated in Table 1 .
Previous studies revealed that S. aureus was responsible for 2.3%-46.3% 5, 9, 14, 15, [18] [19] [20] [27] [28] [29] [30] [31] [32] [35] [36] [37] [42] [43] [44] [45] [46] [47] [48] [49] of all pathogens causing bacteremia among liver recipients and MRSA was 1.6%-41.4%. 5, 9, 14, 15, 18, 19, 27, 35, 36, 44, 45, 49, 50 In a case report, Doucette et al 51 claimed that S. aureus accounted for half of four cases wherein donor-derived bacteremias were transmitted to liver recipients, despite appropriate antibiotic prophylaxis. The incidence rates of S. aureus/MRSA in all pathogens causing bacteremia among liver recipients are shown in Table 2 .
Principle sources of S. aureus/MRSA bacteremia Intravascular catheters were confirmed as the most frequent source of S. aureus bacteremia in several studies. 17, 20, 52, 53 A patient's colonized skin is also a usual source of S. aureus bacteremia after LT. 54 Other studies reported that the principle sources of S. aureus bacteremia in liver recipients included primary infection (including either intravascular catheters or unknown source) (21.4%-57.7%), abdominal or biliary tract (7%-33.6%), lung (6%-55%), urogenital tract 
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Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients (1.3%-17%), gastrointestinal tract (52.8%), endocarditis (3.8%), surgical wounds (1.3%-33%) and donor transmission (1.2%). 4, 14, 15, 21, 25, 34, 35, 41, 45, 46, 51, [55] [56] [57] Risk factors for MRSA colonization/ infection/bacteremia and for S. aureus/ MRSA infection/bacteremia-related mortality
Liver recipients are at a high risk of MRSA colonization because of multiple hospital admissions, prolonged stay in hospital and recent broad-spectrum antimicrobial use. 58 A number of risk factors for MRSA colonization have been recognized by previous studies, including the severity of patients, prior use of antimicrobial, preoperative use of fluoroquinolones, use of invasive medical devices, postoperative bleeding at the surgical site and prolonged stay in intensive care unit. 24, 59, 60 MRSA colonization is generally seen as a factor strongly related to infection in post-LT. [61] [62] [63] [64] Other risk factors for MRSA infection after LT are listed as follows: alcoholic cirrhosis, decreased prothrombin ratio, presence of central lines, being intubated, immunosuppressed status, multiple admissions to the intensive care unit, retransplantation and prolonged hospitalization. 4, 23, 24, 40, 58, 61 Additionally, risk factors such as age 60 years or greater, preoperative use of antimicrobials, operation time (>16 hours) and perioperative dialysis and/or apheresis are also known to increase the risk of MRSA infection. However, postoperative use of fluoroquinolone was negatively associated with acquisition of MRSA. 22, 39, 58 As mentioned in limited number of studies, pre-transplant and post-transplant acquired S. aureus carriage, greater severity of liver disease, hepatocellular carcinoma and infection with immunomodulatory viruses such as cytomegalovirus (CMV) increase the risk of S. aureus bacteremia in liver recipients. 23, 41, 45, 55 
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Liu et al CMV does stimulate certain activities of the host immune system by upregulation of specific T-and B-cell alloimmune responses through innate immune mechanisms or stimulation of alloimmunity via cross-reactive viral antigens, but in aggregate the effects of the virus are immune suppressive. 65 Potential mechanisms of CMV-induced immunosuppression included suppression of CD4 T-lymphocyte activation and proliferation, as well as inhibition of the expression of surface-soluble CD14 in alveolar macrophages. 66, 67 Table 3 provides an overview of risk factors for S. aureus/MRSA infection/bacteremia among liver recipients.
The isolation of S. aureus, per se, was a risk factor for mortality in solid organ transplant recipients with bacteremia. 15 In a single-center retrospective study of 2,959 solid organ transplant patients, Malinis et al 16 suggested an association between pulmonary focus and S. aureus bacteremiarelated mortality. On reviewing the literature it was found that data are scarce focusing on liver recipients with S. aureus bacteremia. Only one previous study conducted by Singh et al 4 documented that MRSA bacteremia accompanied by pneumonia and abdominal infections was associated with mortality in liver recipients. Risk factors for associated mortality in liver recipients with S. aureus/MRSA infection/ bacteremia are displayed in Table 4 .
Antimicrobial resistance of S. aureus
Previous studies confirmed that, among bacteremic LT, 26.3%-100% of S. aureus were methicillin resistant. 4, 14, 18, 26, 27, 34, 35, 39, [44] [45] [46] 49 The resistance rates of MRSA to vancomycin, amikacin and ciprofloxacin were 0%, 50% and 53.5%, respectively. 45 Ye et al 42 analyzed the data from 19 episodes and concluded that 52.6% of S. aureus were resistant to levofloxacin, 26.3% to amikacin and 5.3% to vancomycin. One study conducted by Zhou et al 34 reported that S. aureus was highly resistant to erythromycin and penicillin (resistance rates >90%). Table 5 illustrates the drug resistance rates of S. aureus/MRSA causing bacteremia among liver recipients.
Reasons for the high rates and wide ranges of both S. aureus/MRSA bacteremia and its related mortality
The great number of S. aureus/MRSA bacteremia in LT population is probably explained by a global trend of epidemiology of microbiology, antibiotic prophylaxis such as quinolones for spontaneous bacterial peritonitis, prolonged use of central venous catheters, high immunosuppression required due to the immunity of the allograft and, most importantly, the poor general condition before LT. 10, 62, 68 The high mortality rate in LT population could be partly explained by virulence of Furthermore, bacteremia, per se, could also be a marker of other factors related to higher mortality, comprising poor graft function, surgical complications and prolonged intensive care unit stay. 72 We noticed that there is a wide range of morbidity and mortality of bacteremia between centers, and this phenomenon might result from geographic differences in microbiological environments, along with various diagnostic criteria, severity of the illness, colonization pressure, the frequency of performing active surveillance cultures, immunosuppressive drugs and study designs. As for MRSA bacteremic LT patients, studies differed between the study periods, the follow-up duration, the intrinsic virulence of S. aureus strains or between centers performing the different prophylactic and therapeutic antimicrobial strategies, causing the diversity in outcomes. 73, 74 The death rate also varied significantly for different sources of bacteremia. Singh et al 4 described that mortality was 67% for bacteremic liver recipients accompanied with pneumonia, 6% for those with abdominal infection and 0% for patients with catheter-related infection or wound and urogenital infections.
Diagnosis of MRSA colonization and infection
In the past, the isolation of pathogens by traditional cultures used to take 96 hours, whereas with new methods using the GeneOhm™ MRSA polymerase chain reaction test and GeneXpert MRSA/SA test, only 27.6 and 21.4 hours are required, respectively. 75 Rapid molecular diagnostics within hours rather than days enable the prompt pre-emptive treatment of S. aureus carriers when appropriate. 76, 77 Molecular characterization allows clinicians to know if there is a resistance gene related to antimicrobials, such as mupirocin, or antiseptics such as chlorhexidine in MRSA isolates to propose a future intervention study. 78, 79 Thanks to advances in molecular methods, we are now able to evaluate MRSA isolates and to develop strategies to control and The aforementioned results of high morbidity and mortality among liver recipients highlight the urgency to curtail the incidence of MRSA bacteremia. There are some measures to prevent MRSA bacteremia in liver recipients the same as those in nonimmunosuppressed hospitalized patients, including source control, preservation of kidney function, restriction of the use of invasive devices and equipment, removing all unnecessary catheters at the earliest possible time and minimizing postoperative length of stay in intensive care unit.
MRSA colonization before LT occurred in 5.1%-47.4% of the cases. 23, 55 Up to 87.5% of colonized patients developed MRSA infections, which contained bacteremia. 4, 24, 39, 61, 78, [83] [84] [85] Thus, we should keep a close eye on MRSA colonization. Preoperative and postoperative screening for MRSA nasal carriage is crucial, and control measures of eliminating nasal carriage of S. aureus should be taken. Furthermore, medical workers should take actions to prevent transmission of MRSA from patient to patient, such as hand washing with hydroalcoholic solutions. 17, 24, 86, 87 Intranasal mupirocin 2% ointment with or without a combination of chlorhexidine gluconate body wash could be used to eradicate both methicillin-susceptible S. aureus (MSSA) and MRSA in liver recipients with S. aureus carriage, but mupirocin resistance may exist. [88] [89] [90] [91] Catheter-related bacteremia caused by MRSA was preventable with appropriate prevention strategies. 72 Strict adherence to the principles of intravascular catheter management established by CDC sharply reduced its incidence. [92] [93] [94] Skin antisepsis with chlorhexidine gluconate or daily skin cleansing with 2% chlorhexidine gluconate can also control this type of bacteremia well. 95 Other studies have reported the efficacy of antibiotic impregnated catheters. 96 When serious MRSA infections occur, it is suggested to reduce or remove immunosuppressive agents to elevate host reactivity and to prevent the onset of MRSA bacteremia.
Corticosteroids can block transcription of cytokine genes and nonspecific inhibition of T lymphocytes and macrophages. Maintenance treatment without prednisone, therefore, can decrease the development of MRSA bacteremia.
The treatment for donors with S. aureus colonization and/ or infections and a surveillance of liver recipients of organs from donors with S. aureus bacteremia were also needed, since S. aureus may be transferred in the donated organs and appropriate prophylaxis did not eliminate the risk of transmission. 51, [97] [98] [99] However, the addition of vancomycin or teicoplanin should be reserved for confirmed MRSA sepsis rather than for decolonization therapy for MRSA carriers, because overuse of these glycopeptide antibiotics could be associated with other potential problems such as superinfection. 100 
effects of infection control measures on reducing colonization/infection rates and mortality
The prevalence of newly detected MRSA colonization by active surveillance cultures declined from 8.0% to 5.4%. 40 Russell et al 40 found that the rate of health care-associated MRSA infection declined from 4. Another previous study at a university hospital also reported that despite the number of MRSA-colonized patients went up during a 3-year period, the proportion of MRSA infection cases decreased from 50% to 6% after the successful use of active surveillance cultures, barrier precautions and decolonization therapy for carriers. 87 The incidence of hospital-acquired MRSA cases significantly decreased after a successful hand hygiene promotion program in a district hospital in the UK. 101 In London, researchers at St George's hospital reported that reductions in MRSA rates were strongly associated with reducing the prescribing of cephalosporins and ciprofloxacin. 102 One of the largest transplant centers reported an impact of an aggressive infection control strategy in liver recipients, which decreased the rate of S. aureus bacteremia from 26% to 4%, including positive screening for nasal and rectal colonization, effective isolation strategies and decolonization with intranasal mupirocin therapy. 55 Various strategies could lead to a decline in the proportion of MRSA bacteremia. 37 According to Hashimoto et al, 5 following infection control policies and standard perioperative prophylaxis aimed at decreasing either the risk of MRSA colonization or infection, 
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Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients only 2.1% (5/242) of liver recipients developed S. aureus bacteremia and of these 242 patients, only 1 (0.4%) (1/242) died of bacteremia.
Clinical management of S. aureus bacteremia
Choosing empirical antibiotic therapy while awaiting for the results of blood cultures must take into account susceptibility changes of S. aureus causing bacteremia and the high frequency of MRSA. Currently, glycopeptides (vancomycin, teicoplanin), linezolid, daptomycin, quinupristin-dalfopristin and, more recently, tigecycline are several treatment options for MRSA infection. [103] [104] [105] The standard treatment for MRSA is glycopeptide, which has been widely used, but its current administration to treat MRSA infections has been in great debate because it has a modest effect despite showing in vitro sensitivity. 106 Takatsuki et al 38 had introduced their successful experience of salvage therapy with linezolid after teicoplanin failure for systemic severe MRSA infection, while others 107 demonstrated that none of them was proven to work as good as vancomycin against MRSA.
Vancomycin and daptomycin are the only two FDAapproved agents for the treatment of MRSA bacteremia in the US. Therefore, a recent review still recommended them as the first-line antibiotic therapy for MRSA bacteremia. 108 As far as concentrations of vancomycin were concerned, trough monitoring was recommended to achieve target concentrations of 15-20 μg/mL. 109 It is important to note that vancomycin is less effective for the treatment of MSSA bacteremia and endocarditis when compared with β-lactam agents. 110, 111 Patients receiving empirical vancomycin who are found to have catheter-related bacteremia due to MSSA should be switched to cefazolin. 112 MRSA treated with vancomycin is associated with reduced vancomycin susceptibility and treatment failure. 113 The prevalence of heteroresistant vancomycin-intermediate S. aureus is also increasing; antibiotics with in vitro activity against it comprised linezolid, daptomycin, ceftaroline, tigecycline and quinupristin/dalfopristin. 114 However, drug resistance of S. aureus to these antibiotics is described. 115 Furthermore, according to the black box warning by FDA, tigecycline, which can increase the risk of death, should be reserved only for situations in which alternative treatments are not suitable. 108 Telavancin is a novel lipoglycopeptide antibiotic with potential activity against MRSA. It was successful in treating MRSA bacteremia in some case reports. [116] [117] [118] Nonetheless, in a study involving 73 patients with bacteremic pneumonia, telavancin was not related to a significant difference in cure rate when compared with vancomycin. 119 It is notable that combination therapy for MRSA bacteremia appeared no more effective and was even more harmful than vancomycin monotherapy. Adding gentamicin, rifampin or both to vancomycin offers no meaningful benefit and may confer harm for treating MRSA bacteremia. 120, 121 The addition of a β-lactam antibiotic to vancomycin or daptomycin for treating MRSA bacteremia has unproven benefit. 122 The mortality on day 30 was 41% among those who received combination therapy compared with 7% (1/14) among those who received vancomycin monotherapy in liver recipients with MRSA bacteremia. 4 As far as duration of antibiotic use is concerned, when organs are utilized from donors with S. aureus bacteremia, recipients should receive a relatively long (2-4 weeks) antibiotic course. 51, 123 Based on published guidelines and observational studies, MRSA bacteremia should be administrated intravenous (IV) antibiotic therapy of ≥14 days for uncomplicated bacteremia or ≥28 days for complicated bacteremia. 88, 108, 112 Transplant patients with S. aureus catheter-related bacteremia should receive 4-6 weeks of antimicrobial therapy. 112 For adults with infective endocarditis, IV vancomycin or daptomycin 6 mg/kg/dose IV once daily for 6 weeks is recommended. 109 Infectious disease consultation is nowadays a great concern. It is likely that the reduction in all-cause mortality in patients with S. aureus bacteremia is via improved quality measures of management, including removal of infectious foci, repeat blood culture, echocardiography, appropriate antibiotic therapy and administration of prolonged treatment of complicated infections. 124, 125 A large multicenter cohort study suggested that in the non-transplant population with S. aureus bacteremia, infectious disease consultation is associated with better adherence to quality measures, reduced in-hospital mortality and earlier discharge. 126 In a single-center retrospective study, Malinis et al 16 reported that infectious disease consultation, as one of contributing factors in reducing mortality, was obtained in 65 of 70 (93%) solid organ transplant patients.
Source control by eliminating and/or debriding primary sites of bacteremia was recommended and additional blood cultures 2-4 days after initial positive cultures were needed, especially when vancomycin treatment failed and MRSA bacteremia was persistent. 109 Within the liver, Kupffer cells are optimally positioned within the vasculature to encounter circulating bacteria, which are critical for their clearance from the bloodstream during steady state and during sepsis. [127] [128] [129] Infection and Drug Resistance 2018:11 submit your manuscript | www.dovepress.com
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Kupffer cells contribute to neutrophil recruitment and their dysfunction is a risk factor for post-LT bacteremia. 130 It can be explained by Kupffer cell dysfunction if any case of otherwise unexplained persistent MRSA bacteremia occurs in a post-LT patient, despite having been treated with an appropriate anti-microbial agent.
Prolonged therapy and early evaluation for valve replacement surgery are recommended if prosthetic valve infective endocarditis is confirmed. 109 In addition, all liver recipients with S. aureus bacteremia should be evaluated with echocardiography, preferably by transesophageal echocardiography unless the patient meets criteria for being at low risk. 16, 108 Future research Given the considerable morbidity and mortality in liver recipients with MRSA bacteremia, considerably more work will need to be done to explore more intensive prophylactic measures and effective treatments.
Data are lacking with regard to the risk factors for the development of MRSA bacteremia, particularly its associated mortality, after LT. In addition, most of the literature studies provided just a general comment about preventive measures and did not specifically focus on LT with MRSA bacteremia. The safety and outcomes linked with donor-transmitted MRSA infections are controversial. 4, 14, 51 Chlorhexidine resistance has not been frequently described in MRSA isolates. However, the efficacy of mupirocin prophylaxis on MRSA infection in LT is debatable. 17, 38 Evidence from wellcontrolled studies, therefore, is needed to better confirm the risk factors for MRSA bacteremia and its related mortality, and to better confirm the efficacy of mupirocin in this population thus to form specifically preventive strategies.
Treatment data specific to liver recipients with S. aureus bacteremia are also limited. Since inadequate empirical therapy has been identified as a significant risk factor for bacteremia-related mortality, more funding and clinical trials are urgently needed to explore therapeutic options for MRSA. Data were also particularly scarce regarding the proportion of liver recipients with S. aureus bacteremia who received infectious disease consultation. A future challenge will be to ensure that this patient population benefit from this expert advice and improved care.
Recommendation for prevention and management of S. aureus/MRSA colonization/infection/bacteremia
The incidence of S. aureus bacteremia decreased from 28.3% to 1.3% in our liver recipients when appropriate measures were taken. Our recommendations for management of S. aureus colonization and infection for now are as follows: 1) removing the risk factors for S. aureus/MRSA colonization/infection/bacteremia such as reducing broad-spectrum antibiotics for prophylaxis and using invasive medical devices and central lines, and minimizing postoperative length of stay in the intensive care unit and hospital; 2) improving surgical techniques and reducing intraoperative bleeding and transfusions; 3) using molecular methods to diagnose MRSA colonization and infection; 4) controlling source by eliminating and/or debriding primary sites of bacteremia; 5) preventing transmission of MRSA from patient to patient such as strict hand hygiene measures and effective isolation strategies; 6) treating donors with S. aureus colonization and/ or infections; 7) preoperative and postoperative screening and decolonization therapy for S. aureus/MRSA carriers in liver recipients; and 8) using vancomycin and daptomycin as the first-line antibiotic therapy for MRSA bacteremia.
